TY - JOUR
T1 - Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research
T2 - application to the implementation of pharmacogenetic testing for antidepressant therapy
AU - Salloum, Ramzi G.
AU - Bishop, Jeffrey R.
AU - Elchynski, Amanda L.
AU - Smith, D. Max
AU - Rowe, Elizabeth
AU - Blake, Kathryn V.
AU - Limdi, Nita A.
AU - Aquilante, Christina L.
AU - Bates, Jill
AU - Beitelshees, Amber L.
AU - Cipriani, Amber
AU - Duong, Benjamin Q.
AU - Empey, Philip E.
AU - Formea, Christine M.
AU - Hicks, J. Kevin
AU - Mroz, Pawel
AU - Oslin, David
AU - Pasternak, Amy L.
AU - Petry, Natasha
AU - Ramsey, Laura B.
AU - Schlichte, Allyson
AU - Swain, Sandra M.
AU - Ward, Kristen M.
AU - Wiisanen, Kristin
AU - Skaar, Todd C.
AU - Van Driest, Sara L.
AU - Cavallari, Larisa H.
AU - Tuteja, Sony
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: Despite the increased demand for pharmacogenetic (PGx) testing to guide antidepressant use, little is known about how to implement testing in clinical practice. Best–worst scaling (BWS) is a stated preferences technique for determining the relative importance of alternative scenarios and is increasingly being used as a healthcare assessment tool, with potential applications in implementation research. We conducted a BWS experiment to evaluate the relative importance of implementation factors for PGx testing to guide antidepressant use. Methods: We surveyed 17 healthcare organizations that either had implemented or were in the process of implementing PGx testing for antidepressants. The survey included a BWS experiment to evaluate the relative importance of Consolidated Framework for Implementation Research (CFIR) constructs from the perspective of implementing sites. Results: Participating sites varied on their PGx testing platform and methods for returning recommendations to providers and patients, but they were consistent in ranking several CFIR constructs as most important for implementation: patient needs/resources, leadership engagement, intervention knowledge/beliefs, evidence strength and quality, and identification of champions. Conclusions: This study demonstrates the feasibility of using choice experiments to systematically evaluate the relative importance of implementation determinants from the perspective of implementing organizations. BWS findings can inform other organizations interested in implementing PGx testing for mental health. Further, this study demonstrates the application of BWS to PGx, the findings of which may be used by other organizations to inform implementation of PGx testing for mental health disorders.
AB - Background: Despite the increased demand for pharmacogenetic (PGx) testing to guide antidepressant use, little is known about how to implement testing in clinical practice. Best–worst scaling (BWS) is a stated preferences technique for determining the relative importance of alternative scenarios and is increasingly being used as a healthcare assessment tool, with potential applications in implementation research. We conducted a BWS experiment to evaluate the relative importance of implementation factors for PGx testing to guide antidepressant use. Methods: We surveyed 17 healthcare organizations that either had implemented or were in the process of implementing PGx testing for antidepressants. The survey included a BWS experiment to evaluate the relative importance of Consolidated Framework for Implementation Research (CFIR) constructs from the perspective of implementing sites. Results: Participating sites varied on their PGx testing platform and methods for returning recommendations to providers and patients, but they were consistent in ranking several CFIR constructs as most important for implementation: patient needs/resources, leadership engagement, intervention knowledge/beliefs, evidence strength and quality, and identification of champions. Conclusions: This study demonstrates the feasibility of using choice experiments to systematically evaluate the relative importance of implementation determinants from the perspective of implementing organizations. BWS findings can inform other organizations interested in implementing PGx testing for mental health. Further, this study demonstrates the application of BWS to PGx, the findings of which may be used by other organizations to inform implementation of PGx testing for mental health disorders.
KW - Best–worst scaling
KW - Consolidated Framework for Implementation Research
KW - Pharmacogenetic testing
UR - http://www.scopus.com/inward/record.url?scp=85151765565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151765565&partnerID=8YFLogxK
U2 - 10.1186/s43058-022-00300-7
DO - 10.1186/s43058-022-00300-7
M3 - Article
C2 - 35568931
AN - SCOPUS:85151765565
SN - 2662-2211
VL - 3
JO - Implementation Science Communications
JF - Implementation Science Communications
IS - 1
M1 - 52
ER -